

FOR IMMEDIATE RELEASE

March 30, 2016

Listed Company Name: Eisai Co., Ltd.
 Representative: Haruo Naito
 Representative Corporate Officer and CEO
 Securities Code: 4523
 Stock Exchange Listings: First Section of the Tokyo Stock Exchange
 Inquiries: Sayoko Sasaki
 Vice President, Corporate Affairs
 Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS)
 for the Fiscal Year Ending March 31, 2016**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:

1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Basic earnings per share
Previously announced forecast (A) (Feb. 2, 2016)	556,500	51,000	49,000	37,000	129.00 yen
Currently revised forecast (B)	547,000	51,000	49,000	50,000	174.28 yen
Change in amount (B - A)	-9,500	–	–	13,000	
Percentage of change (%)	-1.7%	–%	–%	35.1%	
(Reference) Business results for the fiscal year ended March 31, 2015	548,465	28,338	25,875	43,453	151.57 yen

2. Reason for revision of the consolidated financial results forecasts

Revenue is forecasted to be ¥547,000 million (down 0.3% from the previous fiscal year) due to the impact of the latest results of the Japan pharmaceutical business and exchange rates.

Operating profit is forecasted to be ¥51,000 million which is unchanged from the previous forecast as the impact from the decrease in revenue will be offset by further progress in cost optimization.

Profit for the period is forecasted to be ¥50,000 million (up ¥13,000 million from the previous forecast), attributable to the transfer of shares in AkaRx Inc. by Eisai's U.S. subsidiary Eisai Inc. as announced today. Furthermore, Eisai intends to set the dividend for the period (second six-month period ending March 31,

2016) at ¥80 per share, with the forecast for the total dividend for the year remaining unchanged at ¥150 per share (same amount as the previous fiscal year).

*Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 30, 2016.
